360 related articles for article (PubMed ID: 17413980)
21. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas.
Diebold J; Deisenhofer I; Baretton GB; Blasenbreu S; Suchy B; Schneiderbanger K; Meier W; Haas CJ; Löhrs U
Lab Invest; 1996 Oct; 75(4):473-85. PubMed ID: 8874380
[TBL] [Abstract][Full Text] [Related]
22. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
23. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
[TBL] [Abstract][Full Text] [Related]
24. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
25. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
[TBL] [Abstract][Full Text] [Related]
26. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
27. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of mammaglobin B in epithelial ovarian carcinomas.
Tassi RA; Bignotti E; Rossi E; Falchetti M; Donzelli C; Calza S; Ravaggi A; Bandiera E; Pecorelli S; Santin AD
Gynecol Oncol; 2007 Jun; 105(3):578-85. PubMed ID: 17343903
[TBL] [Abstract][Full Text] [Related]
29. Ephrin B expression in epithelial ovarian neoplasms correlates with tumor differentiation and angiogenesis.
Castellvi J; Garcia A; de la Torre J; Hernandez J; Gil A; Xercavins J; Ramón y Cajal S
Hum Pathol; 2006 Jul; 37(7):883-9. PubMed ID: 16784989
[TBL] [Abstract][Full Text] [Related]
30. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
[TBL] [Abstract][Full Text] [Related]
31. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
32. Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1alpha/GLUT-1 expression.
Iida T; Yasuda M; Miyazawa M; Fujita M; Osamura RY; Hirasawa T; Muramatsu T; Murakami M; Saito K; Mikami M
Arch Gynecol Obstet; 2008 Jun; 277(6):539-46. PubMed ID: 18026974
[TBL] [Abstract][Full Text] [Related]
33. Comparative proteomics of ovarian epithelial tumors.
An HJ; Kim DS; Park YK; Kim SK; Choi YP; Kang S; Ding B; Cho NH
J Proteome Res; 2006 May; 5(5):1082-90. PubMed ID: 16674097
[TBL] [Abstract][Full Text] [Related]
34. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer.
Dong Q; Kirley S; Rueda B; Zhao C; Zukerberg L; Oliva E
Mod Pathol; 2003 Sep; 16(9):863-8. PubMed ID: 13679449
[TBL] [Abstract][Full Text] [Related]
35. Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression.
Saegusa M; Machida D; Okayasu I
Br J Cancer; 2000 Feb; 82(3):571-8. PubMed ID: 10682668
[TBL] [Abstract][Full Text] [Related]
36. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors.
Choi YL; Kim SH; Shin YK; Hong YC; Lee SJ; Kang SY; Ahn G
Gynecol Oncol; 2005 May; 97(2):379-86. PubMed ID: 15863133
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
38. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
Meinhold-Heerlein I; Bauerschlag D; Hilpert F; Dimitrov P; Sapinoso LM; Orlowska-Volk M; Bauknecht T; Park TW; Jonat W; Jacobsen A; Sehouli J; Luttges J; Krajewski M; Krajewski S; Reed JC; Arnold N; Hampton GM
Oncogene; 2005 Feb; 24(6):1053-65. PubMed ID: 15558012
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components.
Tsanou E; Ioachim E; Briasoulis E; Charchanti A; Damala K; Karavasilis V; Pavlidis N; Agnantis NJ
J Exp Clin Cancer Res; 2004 Dec; 23(4):641-50. PubMed ID: 15743035
[TBL] [Abstract][Full Text] [Related]
40. The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer.
Gryshkova V; Goncharuk I; Gurtovyy V; Khozhayenko Y; Nespryadko S; Vorobjova L; Usenko V; Gout I; Filonenko V; Kiyamova R
Exp Oncol; 2009 Mar; 31(1):37-42. PubMed ID: 19300415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
